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The aim of  this study is to analyze the relations of  Human Epidermal Growth 
Factor Receptor 2 (HER2) expression and E-Cadherin (CDH1) expression in 
breast cancer patients. To date, the synergistic effect of  this CDH1/HER2 
complex is not well clarified. The design of  this study was cross-sectional with 
a total sample of  56 formalin-fixed paraffin tissue blocks that had been 
examined for HER2. Furthermore, CDHI expression was examined using the 
Immunohistochemistry staining technique with the Labeled Streptavidin 
Biotin Complex (LSAB) method. Bivariate analysis was performed using the 
Spearman correlation test with abnormally distributed data (p>0.05). Of  the 
56 data on breast cancer patients, most of  the patients (87.5%) were diagnosed 
at the age of  ≥40 years. The majority of  cancer staging was IIIB, which was 
42.9% of  the total 56 patients. The study results shows that 80.0% of  HER2-
positive patients were in the strong CDH1 group. From these data, there is 
evidence of  correlation between HER2 expression and CDH1 expression in 
breast cancer patients, however this correlation was not significant (p>0.05).  
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INTRODUCTION  
Breast cancer is the leading cause of  cancer-
related deaths in women in both developed and 
developing countries (WHO, 2018). Every year, 
there are 2.1 million cases of  female breast cancer 
worldwide. In 2018, an estimated 627,000 women 
died from breast cancer, which is about 15% of  all 
cancer deaths among women (UICC, 2019). 
In 2018, in Indonesia there were 22,692 
people who died from breast cancer (UICC, 2019). 
In the Department of  Surgery, M. Djamil Hospital 
Padang, there were 509 patients between 2008 and 
2017 (Harahap & Khambri, 2018). The low 
survival rates in developing countries are mainly 
due to the lack of  adequate early detection and 
diagnosis programs and care facilities, so that 
many patients are found already at the end-stage 
and have metastasized. In addition, inadequate 
therapy can also lead to relapse (White et al., 2014). 
Human Epidermal Growth Factor 
Receptor 2 (HER2) is a proto oncogene that 
functions to stimulate cell proliferation by 
activating tyrosine kinase. Physiologically, HER2 
will stop working if  the cells needed are sufficient. 
However, in cancer cells HER2 amplification 
occurs. This will activate the Ras/Raf/mitogen-
activated protein kinase (MAPK) and 
phosphoinositide 3-kinase/Akt (PI3K/Akt) 
pathways (Dey, Leyland-Jones, & De, 2016; Fink 
& Chipuk, 2013). Activation of  these pathways 
causes proliferation, survival, differentiation, 
angiogenesis, and invasion of  tumor cells (Baker, 
Zlobin, & Osipo, 2014; Iqbal & Iqbal, 2014; Vu & 
Claret, 2012). 
Elastin-Cadherin/E-Cadherin/CDH1 is 
expressed in the epithelial tissue of  the breast and 
functions as an adhesive (adhesion) between 
epithelial cells. E-cadherin binds with β-catenin to 
form the E-cadherin-β-catenin complex to 
maintain cell adhesion. E-cadherin is thought to 
have tumor suppressor properties (tumor 
suppressor gene) where its absence is associated 
with carcinogenesis and metastasis. Down 
regulation of  E-cadherin releases free β-catenin 
which activates the Wnt signaling pathway. At the 
same time, the reduction in E-cadherin will trigger 
an epithelial-to-mesenchymal transition (EMT). 
EMT is a process of  changing the epithelium into 
mesenchyme which plays a role in carcinogenesis 
and metastasis (Darwin, Elfi, & Elvira, 2017). In 
addition, this cell adhesion system can be 
disrupted by the tyrosine kinase c-erbB-
2/HER2/neu (Januardi, Pualilin, Kadir, & 
Prihantono, 2019). 
This synergistic effect of  the E-
cadherin/HER2 complex is not well clarified. In 
several studies that have been done, it was found 
that there was no relationship between e-cadherin 
expression and HER2 (Januardi et al., 2019; 
Panigoro, Karsono, & Sari, 2017). This conclusion 
is supported by Ingthorsson et al. (2016) who 
found that HER2 could trigger EMT directly 
without the involvement of  E-cadherin. Thus, this 
allows E-cadherin expression to remain strong in 
the event of  HER2 overexpression. However, in 
another study it was found that E-cadherin 
inactivation led to overexpression of  HER2 with a 
worse impact on cancer prognosis. (Corso, 
Bonanni, & Veronesi, 2018). Recently, a study in 
China has formulated a HER2-ATF4-ZEB1-e-
cadherin pathway. They proved that there was a 
real reciprocal relationship between HER2 status 
and E-cadherin expression. It was stated that an 
increase in HER2 would result in downregulation 
of  E-cadherin (Zeng, Sun, Li, Xiao, & Chen, 
2019). 
This study aims to analyze the relationship 
between HER2 expression and E-cadherin 
expression in breast cancer patients. While in other 
previous studies the expression of  CDH1 
examined only from HER2 positive, this study 
analyze CDH1 expression from both HER2 
positive and negative. The results of  this study are 
expected to increase knowledge about the role of  
E-cadherin in the diagnosis and prognosis of  
HER2-Positive breast cancer patients. 
Furthermore, clinicians may also consider routine 
E-cadherin screening for breast cancer patients, 
particularly HER2-Positive, to predict recurrence 
and patient prognosis. 
Relations of  Human Epidermal Growth Factor Receptor 2 (HER2) … Rahimi et al. | 3 
 
 
MATERIALS AND METHODS  
 
Study Design 
This study is a cross-sectional study, in which 
the independent and dependent variables are 
examined at one particular time. 
 
Population and Samples 
The population of  this study was the results 
of  breast cancer biopsy/surgery in the 2018-2020 
period. The sample is a part of  the population that 
has exclusion and inclusion criteria. The inclusion 
criteria in this study were: i) breast cancer cases of  
women who had undergone biopsy/surgery in the 
2018-2020 period; ii) have a histopathological 
examination result and have a medical record at 
RSI Ibnu Sina Padang or RSB Ropanasuri Padang; 
iii) the biopsy/surgery results are stored in the 
form of  a paraffin block; and iv) have had the 
results of  HER2 Immunohistochemistry (IHC) 
tests. The exclusion criteria in this study were: i) 
incomplete medical record; ii) paraffin block not 
found; and iii) no IHC staining results were 
obtained even though they had been cut twice. To 
determine the sample size (n), this study used the 











where P is the proportion in previous studies, 
which is 17% (He, Lv, Song, & Zhang, 2019); Zα 
= 1,96 and d is absolute precision = 0,1. 
After entering these numbers into the above 
formula, the result was 54.02 ≈ 54. Thus, in this 
study the minimum sample size was 54 tissue 
paraffin blocks. To anticipate the possibility of  
dropping out, 70 blocks of  paraffin were collected. 
 
Research Procedure 
During the 2018-2020 period there were 332 
cases of  breast cancer at RSI Ibnu Sina Padang and 
RSB Ropanasuri Padang. From this number, 70 
cases had complete medical records, 
biopsy/surgery tissue results were stored in the 
form of  paraffin blocks, and had IHC examination 
results, especially HER2. Furthermore, 
examination of  CDH1 expression (antibody: 
Santa Cruz, USA) was performed using the IHC 
staining technique. 
The CDH1 IHC staining technique using the 
Labelled Streptavidin Biotin Complex (LSAB) 
method was performed using a manual procedure. 
After the procedure, the preparation is viewed 
under a binocular light microscope (Olympus 
CX22 series) to assess CDH1 expression. A total 
of  14 paraffin blocks did not get stained even 
though they had been cut twice. Thus, only 56 




At the beginning of  the study, a data 
normality test was carried out to determine 
whether the data was normally distributed or not 
normally distributed using the Kolmogorov 
Smirnov test (n>30). If  the p value >0.05, the data 
is normally distributed and continued using 
parametric analysis and vice versa. The 
presentation of  categorical research variables is 
presented in the form of  a frequency distribution 
table and narrative. 
Bivariate analysis was conducted to see the 
relationship between variables, based on the 
purpose of  this study, the bivariate analysis carried 
out was the Pearson correlation test if  the data 
were normally distributed, and the Spearman if  
the data were not normally distributed. The 
research data analysis was carried out at the 
confidence level of  95% CI (α = 0.05), if  the 
results obtained were p value <0.05, there was a 
significant relationship. Data processing and 
analysis was carried out with the SPSS 25 program. 
 
Ethics Statement 
This study was conducted after obtaining 
Research Ethics Approval No. 
308/KEP/FK/2020 obtained from the Research 
Ethics Committee of  Medical Faculty, Universitas 
Andalas. The results of  ethical approval are used 
as the ethical basis for this study. 
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RESULTS AND DISCUSSION 
The 56 data on breast cancer patients, most 
of  the patients (87.5%) were diagnosed at the age 
of  40 years or more. There were more cases of  
breast cancer diagnosed for the first time in old age 
(≥ 40 years) than at young age. The youngest age 
when breast cancer was first diagnosed was 28 
years old and the oldest at 70 years old with an 
average patient age of  52.6 years. For the largest 
stage is IIIB, which is valued at 42.9%. There were 
25 positive HER2 (+3) expressions and 38 strong 
CDH1 (+2 and +3) expressions. The 
characteristics of  the samples examined are shown 
in Table 1. 
 
Table 1. Sample Characteristics 
Characteristics N % 
Age at diagnosis 
< 40 years old 



























































HER2 expression was assessed by a scoring 
system according to ASCO guidelines (Wolff  et al., 
2018), namely 0, +1, +2, and +3. Where a score 
of  +3 is categorized as positive; 0 and +1 are 
categorized as negative; whereas for a score of  +2 
it is recommended to examine in situ hybridization 
(ISH). Due to the high cost of  ISH screening, very 
few patients are able to do it. So for therapeutic 
purposes, a score of  +2 is categorized as negative. 
In this study, scores of  0, +1, and +2 were 
categorized as negative HER2 and scores of  +3 
were categorized as positive HER2. 
There were 25 patients (44.6%) of  positive 
HER2 expression and 31 patients (55.4%) 
negative HER2. Figure 1 shows the results of  
negative (a) and positive (b) HER2 IHC staining. 
CDH1 expression was classified based on the 
intensity of  staining which consisted of  4 
categories 0 (negative), +1 (weak), +2 (moderate), 
and +3 (strong). For practical and statistical 
purposes, the researcher categorized the cases as 
weak (0, +1) and strong (+2, +3) (ElMoneim & 
Zaghloul, 2011). The number of  strong CDH1 
expression was 38 patients. Meanwhile, 18 patients 
had weak CDH1 expression. Figure 2 shows the 
results of  IHC staining on weak (a) and strong (b) 
CDH1. In this study, it was found that breast 
cancer patients with positive HER2 expression 
had the strongest CDH1 group, which was 80.0% 
(20 patients), as shown in Table 2. From this data 
there was a tendency that the higher the HER2 
score, the stronger the CDH1. However, the 
statistical test results of  this correlation are not 
very significant, the value of  p = 0.083.
  




Figure 1. IHC staining results (a) HER2 +1/Negative, (b) HER2 +3/Postive 
 
  
Figure 2. IHC staining results (a) CDH1+1/Weak, (b) CDH1 +3/Strong 
 
 




Negative (0, +1, +2) Positive (+3) 
CDH1   
0.083 Weak (0, +1) 13 (41.9%) 5 (20.0%) 
Strong (+2, +3) 18 (58.1%) 20 (80.0%) 
 
Similar results were found by Younis et al., 
(2007), that positive HER2 expression has a strong 
CDH1 which is as much as 70.0% of  the study 
sample. However, this study concluded that there 
was no significant relationship between CDH1 
expression and HER2 expression (p = 0.69). The 
same conclusion is also drawn by Singhai et al. 
(2011) which found 87% of  the patient group with 
positive HER2 expression had strong CDH1. Not 
much different, Horne et al. (2018) found that 744 
(86.3%) breast cancer patients had positive HER2 
scores with strong CDH1 scores.  
Research on the relationship between HER 
expression and CDH1 expression has not been 
widely conducted in Indonesia. Until now, there 
has only been one study conducted by Januardi et 
al., (2019). They concluded that there was no 
significant correlation (p = 0.753) between HER2 
expression and CDH1 expression in breast cancer 
patients. It was also found that patients with 
positive HER2 had more weak CDH1 expression 
(34.8%) than strong CDH1 expression (30.4%). 
The same conclusion is reached by Pang et al., 
(2013) in China, there was no statistical correlation 
a b 
a b 
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between HER2 expression and CDH1 expression 
(p = 0.92). In addition, this study also found that 
the higher the HER2 expression, the weaker the 
CDH1 expression. 
From these reports, it is known that the 
expression of  E-Cadherin is still inconsistent in 
the field of  oncology. Many reports mention that 
E-Cadherin plays a role in carcinogenesis and 
metastasis. However, there are also many reports 
that conclude that there is no role for E-Cadherin 
in carcinogenesis and metastasis. In theory, it is 
known that the functional loss of  E-cadherin is the 
most important feature of  tumor cell formation 
and spread through the epithelial-to-mesenchymal 
transition (EMT) (Li, Yin, Zhang, Liu, & Chen, 
2017). The possible role of  EMT as a mechanism 
for carcinogenesis, especially in invasive, 
metastatic cell formation and drug resistance, has 
been the subject of  intensive study over the past 
few years and provides tremendous advances in 
clinicians' understanding of  this phenomenon 
(Kalluri & Weinberg, 2009). The loss of  E-
cadherin expression is widely seen as one of  the 
important and defining events in the development 
of  EMT. Since the EMT process is characterized 
by loss of  adhesion cells, it is intuitive to assume 
that regulation of  E-cadherin expression is 
necessary for EMT to occur (Baranwal & Alahari, 
2009). 
The theory of  E-cadherin re-expression at an 
advanced stage was strengthened by data from this 
study where the most stage was IIIB. In the 
literature, it is stated that stage IIIB means the 
cancer has spread to the chest wall and has 
metastasis to several nearby nodes/lymph nodes 
(Hammer, Fanning, & Crowe, 2008). This is also 
supported by the fact in the field that some of  the 
paraffin blocks examined were the result of  biopsy 
from nodes/lymph nodes of  breast cancer 
patients. So, in this study it can be concluded that 
there has been re-expression of  E-cadherin in 
HER2-positive patients. 
From this explanation, it can be concluded 
that there is a relationship between HER2 
expression and E-cadherin expression in breast 
cancer patients. However, in this study the 
relationship was not statistically significant which 
might be due to several limitations in this study, 
including (1) the proportion of  samples with 
known HER2 scores and E-cadherin examination 
was not balanced due to the limited number of  
samples; (2) the results of  biopsy of  breast cancer 
patients. those who were examined for IHC were 
not uniform, some were primary tumors, the rest 
were nodes/KGB; and (3) some of  the paraffin 
blocks borrowed from the hospital had immature 
conditions so that when they were examined the 





80.0% of  HER2 positive patients were in 
the strong CDH1 group. There was a correlation 
between HER2 expression and CDH1 expression 
in breast cancer patients, but this correlation was 
not significant (p>0.05). The existence of  this 
correlation can be a basis for consideration of  
carrying out a CDH1 examination to help 
diagnose and predict prognosis in breast cancer 
patients with positive HER2. Further researches 
are suggested to use different examination 
techniques such as FIS and other sampling 
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